




美迪西CGT研发



CAR-T

CAR-T Chimeric Antigen Receptor T-Cell Immunotherapy

T CAR T CAR-T CAR-T
B


T CAR T CAR
T

CAR-T

CAR-T

CAR-T

CAR-T





NK (natural killer)
CAR-NK

CAR-T

CAR NK

CAR-NK

T

NK

TCR T
“(Off-the-Shelf





TIL (TILs) T NK CD3+ CD8+ T
TIL TIL IL-2 TIL

TIL	T	60%+	T
CAR-T			CAR T
TCR-T	T	0.5%	TCR T
TIL		CAR-T/TCR-T	

RNA


/

AAV Ad

LV LNP T CAR-T

CGT

-
-
-



PD-1 shRNA
PD-1

CAR

T


PD-1
CAR-T

CAR-T

PD-1


PD-1
CAR-T

CAR-T




Plasmid containing PD-1 knockdown sequence^[4]

CAR-T



CAR-T

CAR-T



Mock-T



-
- IFN- γ
- CAR-T

-
-
-

- Bioluminescent Imaging BLI

-

- ELISA MSD


-



- +
- + CDX
- + PDX
- PBMC HSC +
- +


- +
- + CDX
- PBMC HSC +
-

- + CDX
- + PDX
- +
- + PBMC HSC +
-



Groups	MST	%T/C _{MST}	P-Value
Vehicle	16.5	/	/
CAR T+	>65	>520	P<0.001

Survival proportions of Raji-luc Systemic Xenograft Model




Raji-luc

hPBMC

CAR-T

A549-Target A/A549-Target B Xenograft Tumor Model in Female B-NDG Mice



- B-NDG ~20 g
- A549-Target A+/A549-Target B (1:1)
5×10⁶ cells/mouse
- CAR-T+ Cells, IV, QDx1

CAR-T

CGT


-
-
-
-
-
-
-
-

PCR




PCR

DNA



(qPCR)



()

qPCR

mRNA

PCR RT-qPCR

mRNA

PCR RT-qPCR

•

·ELISA FIA

·ECL

·Western blotting





[1] Yi-Ju Chen, et al. CAR-T: What Is Next? Cancers. 2023 Jan 21;15(3):663.doi: 10.3390/cancers15030663.

[2] Ana Rosa Saez-Ibañez, et al. Landscape of cancer cell therapies: trends and real-world data. Nat Rev Drug Discov. 2022 Sep;21(9):631-632. doi: 10.1038/d41573-022-00095-1.

[3] Leisheng Zhang, et al. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomark Res. 2022 Mar 18;10(1):12. doi: 10.1186/s40364-022-00364-6.

[4] Jing-E Zhou, et al. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. Biomed Pharmacother. 2021 May;137:111339. doi: 10.1016/j.biopha.2021.111339.



400-780-8018
www.medicilon.com.cn

marketing@medicilon.com
585